Live feed
Filing
SCHEDULE 13G/A
SCHEDULE 13G/A0001875620-25-000021·Inhibikase Therapeutics, Inc.
Schedule 13G ownership disclosure
Inhibikase Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 45719W205
Event date: 2025-06-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Sands Capital Life Sciences Pulse Fund II, L.P.
Shares: 10,950,000.00 · Class: 14.7%
- Sands Capital Alternatives, LLC
Shares: 10,950,000.00 · Class: 14.7%
- SANDS FRANK M.
Shares: 10,950,000.00 · Class: 14.7%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001875620-25-000021
- Form type
- SCHEDULE 13G/A
- Filer
- Inhibikase Therapeutics, Inc.
- CIK
- CIK 1750149
- Filed
- Aug 13, 2025
- Reporting period
- Jun 30, 2025
- Description
- Schedule 13G beneficial ownership